Diabetomics, Inc. With a focus on alleviating the economic and public health burden of maternal health and diabetes, Diabetomics offers a range of products to aid in early detection and monitoring. Their flagship product, Lumella®, is the first and only point-of-care test for early detection of preeclampsia and gestational diabetes.

This groundbreaking test allows for quicker diagnosis and proactive management of these conditions, ensuring the best possible outcomes for expectant mothers. Furthermore, Diabetomics offers Insudex®, another first and only point-of-care test, which aids in the early detection of type-1 diabetes and LADA (Latent Autoimmune Diabetes in Adults). This enables individuals at risk of these conditions to be identified and treated promptly, improving their quality of life.

In addition to these tests, Diabetomics provides Glucema®, the first and only point-of-care saliva test for diabetes monitoring. This user-friendly test simplifies diabetes management by allowing individuals to conveniently monitor their blood sugar levels with ease. Diabetomics is committed to developing groundbreaking solutions to improve diagnostics and patient care.

Their dedication to innovation and non-invasive testing makes them a leader in the medical diagnostics industry